Spike His Tag Protein, SARS-CoV-2(R682S,R685S,K986P&V987P)
Spike His Tag Protein, SARS-CoV-2(R682S,R685S,K986P&V987P)
Product Details
Product Details
Product Specification
| Species | SARS-CoV-2 |
| Synonyms | 2019 nCOV Spike S蛋白;S protein; Spike glycoprotein; S glycoprotein; COVID-19 |
| Accession | P0DTC2 |
| Amino Acid Sequence |
Val16-Lys1211 (R682S, R685S, K986P&V987P)
VNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPSRASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKGGGSHHHHHHHH
|
| Expression System | HEK293 |
| Molecular Weight | 130-180kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Endotoxin | <1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, 5% trehalose, pH7.4. |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. Yuejun Shi, Jiale Shi, Limeng Sun, Yubei Tan, Gang Wang, Fenglin Guo, Guangli Hu, Yanan Fu, Zhen F Fu, Shaobo Xiao.Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins. J Virol. 2021 Mar 10;95(7):e02284-20. Epub 2021 Jan 7. |
Background
Coronaviruses that infect humans belong to the
Alpha-coronavirus (including HCoV-229E) and Beta-coronavirus (including
SARS-CoV and SARS-CoV-2) genera. In particular, SARS-CoV-2 is currently a major
threat to public health worldwide. The spike (S) homotrimers bind to their
receptors via the receptor-binding domain (RBD), which is a major target to
block viral entry.our results reveal different vaccine strategies for coronaviruses, and
S-trimer is better than RBD as a target for vaccine development
in Alpha-coronavirus Our findings will provide important implications
for future development of coronavirus vaccines. Outbreak of coronaviruses,
especially SARS-CoV-2, poses a serious threat to global public health.
Development of vaccines to prevent the coronaviruses that can infect humans has
always been a top priority. Coronavirus spike (S) protein is considered as a
major target for vaccine development. Currently, structural studies have shown
that Alpha-coronavirus (HCoV-229E)
and Beta-coronavirus (SARS-CoV and SARS-CoV-2) RBDs are in
"lying" and "standing" states in the prefusion S-trimer
structure. Here, we evaluated the ability of S-trimer and RBD to induce
neutralizing antibodies among these coronaviruses. Our results showed that the
S-trimer and RBD are both candidates for subunit vaccines
in Beta-coronavirus (SARS-CoV and SARS-CoV-2) with a RBD
"standing" state. However,
for Alpha-coronavirus (HCoV-229E) with a RBD "lying" state,
the S-trimer may be more suitable for subunit vaccines than the RBD. Our
results will provide novel ideas for the development of vaccines targeting S
protein in the future.
